2018-12-12 REL 2018-05-23 RCSB RCSB 2018-06-13 2018-06-13 REGN3471 antibody Fab in complex with Ebola virus GP Turner H, Murin CD, Ward AB Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion Jr. R, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. J. Infect. Dis. 218 S612 S626 2018 29860496 doi:10.1093/infdis/jiy285 1537-6613 emd_7902.map.gz Image stored as Reals 80 80 80 0.0 0.0 0.0 79.0 79.0 79.0 80 80 80 328.0 328.0 328.0 90.0 90.0 90.0 X Y Z -15.897512000000001 14.543581 -0.0010277 0.9724852 1
4.1 4.1 4.1 3.5 REGN3471 antibody Fab in complex with Ebola virus GP 1 REGN3471 antibody Fab in complex with Ebola virus GP
Fab fragment generated by proteolytic cleavage of IgG antibody with papain.
protein REGN3471 antibody Fab in complex with Ebola virus GP
Fab fragment generated by proteolytic cleavage of IgG antibody with papain.
Ebola virus - Mayinga, Zaire, 1976 false Drosophila melanogaster S2 pMT-puro NONE LAB6 30.0 BRIGHT FIELD 1000.0 FLOOD BEAM TVIPS TEMCAM-F416 (4k x 4k) 2.2 FEI TECNAI SPIRIT SIDE ENTRY, EUCENTRIC 120 52000.0 70 particle 0.02 7.4
Solution was made from 10x concentration stock.
 Stained using 2% uranyl formate on carbon-coated grids. singleParticle EMAN2 21.0 FSC 0.5 CUT-OFF C3 20266